Julie C. Reddan, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 701 Dellwood St S, Cambridge, MN 55008 Phone: 763-689-8700 Fax: 763-688-7941 |
News Archive
Boehringer Ingelheim Pharmaceuticals, Inc. today announced that The Lancet published results from a phase I study investigating the effects of idarucizumab, an investigational agent, in reversing the anticoagulant effect of dabigatran in healthy volunteers. The data demonstrate that complete reversal was achieved following administration of idarucizumab.
A new study shows that it is possible to selectively target and block a particular microRNA that is important in liver cancer. The findings might offer a new therapy for this malignancy, which kills an estimated 549,000 people worldwide annually.
Bio-Path Holdings, Inc.,, a biotechnology company with drug development operations in Houston, Texas, announced today that the first patient has been dosed in a Phase I study of its cancer drug candidate, Liposomal Grb-2 (L-Grb-2 or BP-100-1.01), in patients with Acute Myeloid Leukemia (AML), Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL) or Myelodysplastic Syndrome (MDS).
On behalf of the Colorectal Cancer Association of Canada, I would like to thank Minister Bolduc and the Ministère de la Santé et des Services Sociaux for taking the first steps to implement the Colorectal Cancer Screening program in Quebec.
› Verified 3 days ago